Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02089230

Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of MEK162 that can be given to patients with relapsed and/or refractory AML, MDS, or ALL.

Status: 
Recruiting
Study Date: 
Fri, 08/01/2014 to Wed, 08/01/2018
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: MEK 162 Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle. Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I.